Clinical trials: Hematologic Disorders
Iron Deficiency Anemia, Heavy Menstrual Bleeding
Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Iron deficiency anemia affects over half of girls and young women with heavy periods and is the most common cause of anemia worldwide.
- Conditions
- Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
- Trial name
- NCT05007899
- Testing
- Ferrous sulfate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of the NOSE Study is to carefully examine the efficacy and safety of 3 nasal sprays (bevacizumab, estriol, and tranexamic acid), compared to placebo, for the treatment of HHT related nosebleeds.
- Trial name
- NOSE (NCT01408030)
- Testing
- Sterile saline, Bevacizumab, Estriol
- Where
- 6 sites in United States
- Volunteers
- 123 people
- Sponsor
- James Gossage
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Sickle Cell Anemia
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
The primary goal of the Phase III TWiTCH trial is to compare 24 months of alternative therapy (hydroxyurea) to standard therapy (transfusions) for pediatric subjects with sickle cell anemia and abnormally high (≥200 cm/sec)…
- Trial name
- TWiTCH (NCT01425307)
- Testing
- Hydroxyurea
- Volunteers
- 159 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Myeloid Leukemia
Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy
Fatigue, reduced quality of life and declines in physical function are common in patients undergoing chemotherapy for acute myeloid leukaemia (AML).
- Trial name
- NCT01170598
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Toronto Rehabilitation Institute
Non Hodgkin Lymphoma, Follicular Lymphoma
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma…
- Conditions
- Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma
- Trial name
- NCT03133221
- Testing
- Zydelig
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis C
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
This is a randomized, multi-site, placebo-controlled trial of a fixed dose combination (FDC) of grazoprevir (MK-5172) 100 mg + elbasvir (MK-8742) 50 mg in participants with chronic Hepatitis C Virus (HCV) genotype (GT) 1, GT4 or…
- Trial name
- NCT02252016
- Testing
- Grazoprevir + Elbasvir
- Volunteers
- 159 people
- Sponsor
- Merck Sharp & Dohme LLC
Sickle Cell Disease
A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
Majority of patients who are eligible for allogeneic HSCT for cure of severe sickle cell disease lack a matched family donor. This study aims for cure of sickle cell disease by performing unrelated donor (outside family)…
- Trial name
- NCT01279616
- Testing
- Fludarabine monophosphate, Rituximab, Busulfan
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nationwide Children's Hospital
Myeloma, Stem Cell Transplantation
Lenalidomide and High-Dose Melphalan
The goal of this clinical research study is to find the highest tolerable dose of the combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to patients with multiple myeloma who will receive…
- Trial name
- NCT01079936
- Testing
- Lenalidomide, Melphalan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Aflibercept for Relapsed Multiple Myeloma
This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment.
- Trial name
- NCT00437034
- Testing
- aflibercept
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Leukemia
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
- Conditions
- Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT00709592
- Testing
- Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Virginia Commonwealth University
Anemia, Leukemia
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
This is a single-center, single arm, open-label study of oral lenalidomide monotherapy administered to red blood cell (RBC) transfusion dependent adult subjects with Diamond-Blackfan Anemia (DBA).
- Conditions
- Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT01034592
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jason Robert Gotlib
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Anemia
ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion
The purpose of this study is to determine if there is a difference in outcomes between liberal transfusion (transfusing when hemoglobin drops below a set higher value number) and conservative transfusion (transfusing when…
- Trial name
- ORACL (NCT02972593)
- Testing
- Blood and blood products for transfusion
- Volunteers
- 161 people
- Sponsor
- Indiana University
Beta-thalassemia Major, Hemosiderosis
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available.
- Conditions
- Beta-thalassemia Major, Hemosiderosis, Iron Overload, Rare Anemia
- Trial name
- ESCALATOR (NCT00171301)
- Testing
- Deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in…
- Trial name
- NCT02076009
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 145 sites in United States, Australia and 16 more
- Volunteers
- 569 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple…
- Trial name
- EVOLVE (NCT03430011)
- Testing
- JCARH125, JCARH125 + anakinra
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic Neoplasm
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Primary Objective: To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance…
- Trial name
- JAKARTA (NCT01437787)
- Testing
- SAR302503
- Where
- 101 sites in United States, Australia and 23 more
- Volunteers
- 289 people
- Sponsor
- Bristol-Myers Squibb
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Daprodustat administration has the potential, by virtue of increasing hypoxia-inducible factor (HIF) levels, to increase oral iron absorption and incorporation into hemoglobin (Hgb).
- Trial name
- NCT03457701
- Testing
- Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.